{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045687761408.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2337/dc13-2112"}},{"identifier":{"@type":"URI","@value":"https://diabetesjournals.org/care/article-pdf/37/1/9/618332/9.pdf"}}],"dc:title":[{"@value":"The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n                  <jats:title>OBJECTIVE</jats:title>\n                  <jats:p>The Diabetes Control and Complications Trial (DCCT) was designed to test the glucose hypothesis and determine whether the complications of type 1 diabetes (T1DM) could be prevented or delayed. The Epidemiology of Diabetes Interventions and Complications (EDIC) observational follow-up determined the durability of the DCCT effects on the more-advanced stages of diabetes complications including cardiovascular disease (CVD).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS</jats:title>\n                  <jats:p>The DCCT (1982–1993) was a controlled clinical trial in 1,441 subjects with T1DM comparing intensive therapy (INT), aimed at achieving levels of glycemia as close to the nondiabetic range as safely possible, with conventional therapy (CON), which aimed to maintain safe asymptomatic glucose control. INT utilized three or more daily insulin injections or insulin pump therapy guided by self-monitored glucose. EDIC (1994–present) is an observational study of the DCCT cohort.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS</jats:title>\n                  <jats:p>The DCCT followed &gt;99% of the cohort for a mean of 6.5 years and demonstrated a 35–76% reduction in the early stages of microvascular disease with INT, with a median HbA1c of 7%, compared with CONV, with a median HbA1c of 9%. The major adverse effect of INT was a threefold increased risk of hypoglycemia, which was not associated with a decline in cognitive function or quality of life. EDIC showed a durable effect of initial assigned therapies despite a loss of the glycemic separation (metabolic memory) and demonstrated that the reduction in early-stage complications during the DCCT translated into substantial reductions in severe complications and CVD.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS</jats:title>\n                  <jats:p>DCCT/EDIC has demonstrated the effectiveness of INT in reducing the long-term complications of T1DM and improving the prospects for a healthy life span.</jats:p>\n               </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137045687761408","@type":"Researcher","foaf:name":[{"@value":"David M. Nathan"}],"jpcoar:affiliationName":[{"@value":"Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Data Coordinating Center, George Washington University, Biostatistics Center, Bethesda, MD"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01495992"},{"@type":"EISSN","@value":"19355548"}],"prism:publicationName":[{"@value":"Diabetes Care"}],"dc:publisher":[{"@value":"American Diabetes Association"}],"prism:publicationDate":"2013-12-11","prism:volume":"37","prism:number":"1","prism:startingPage":"9","prism:endingPage":"16"},"reviewed":"false","url":[{"@id":"https://diabetesjournals.org/care/article-pdf/37/1/9/618332/9.pdf"}],"createdAt":"2013-12-27","modifiedAt":"2022-03-13","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050851275421845120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice."}]},{"@id":"https://cir.nii.ac.jp/crid/1360025431131892480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285712830608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Status and trends in the use of insulin analogs, insulin delivery systems and their association with glycemic control: comparison of the two consecutive recent cohorts of Japanese children and adolescents with type 1 diabetes mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617513536768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298754815936512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Glycemic Control after Initiation of Anti-VEGF Treatment for Diabetic Macular Edema"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189169521536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Protective role of sulphoraphane against vascular complications in diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848663851133184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567365056256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"<scp>Long‐term</scp>\n                    efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled\n                    <scp>52‐week</scp>\n                    outcomes from the\n                    <scp>DEPICT</scp>\n                    ‐1 and ‐2 studies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593739614592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Epigenetic Alterations in Podocytes in Diabetic Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861705584342656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Epigenetic memory contributing to the pathogenesis of AKI-to-CKD transition"}]},{"@id":"https://cir.nii.ac.jp/crid/1390016107125965056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Targeting DNA Methylation in Podocytes to Overcome Chronic Kidney          Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390578393608369024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Nighttime hypoglycemia in Japanese children with type 1 diabetes mellitus treated with multiple daily injection insulin therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390859073051593600","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Association of Impaired Awareness of Hypoglycemia with Driving Safety and Hypoglycemia Problem-solving Abilities among Patients with Type 1 Diabetes in Japan: The PR-IAH Study"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842060125824","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Altered DNA methylation in kidney disease : useful markers and therapeutic targets"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.2337/dc13-2112"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.0332-22_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.1016/j.kint.2024.10.031_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.1515/jpem-2018-0329_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.1002/dmrr.3430_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.1007/s10157-022-02181-5_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.3390/jcm11164659_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.3109/13880209.2016.1138314_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.2302/kjm.2022-0017-ir_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej22-0379_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.2337/dc18-0623_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.1111/dom.14248_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.3389/fphar.2021.759299_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.1016/j.jbc.2021.100761_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"},{"@type":"CROSSREF","@value":"10.3389/fmolb.2022.1003227_references_DOI_726wwUgSnQVmxmeiJNqVgc6Z4bN"}]}